MKA
NKTR icon

M. Kulyk & Associates’s Nektar Therapeutics NKTR Stock Holding History

M. Kulyk & Associates’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,333
Closed -$13.6K – 110
2025
Q1 		$13.6K Hold
1,333
– – ﹤0.01% 101
2024
Q4 		$18.6K Hold
1,333
– – ﹤0.01% 105
2024
Q3 		$26K Sell
1,333
-367
-22% -$7K 0.01% 114
2024
Q2 		$31.6K Buy
+1,700
New +$35.8K 0.01% 110

Other funds holding NKTR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

M. Kulyk & Associates's NKTR Position: Q2 2025 in Review

M. Kulyk & Associates sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 1,333 shares — an estimated $13.6K sold.

M. Kulyk & Associates first reported a position in NKTR in Q2 2024 and held it in 4 quarters. The position peaked at $31.6K in Q2 2024. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.

  • M. Kulyk & Associates reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • M. Kulyk & Associates sold 1,333 Nektar Therapeutics shares in Q2 2025, an estimated $13.6K.
  • M. Kulyk & Associates first reported a position in Nektar Therapeutics in Q2 2024 and held it in 4 quarters.
  • M. Kulyk & Associates's Nektar Therapeutics position peaked at $31.6K in Q2 2024.
  • 109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.

Based on M. Kulyk & Associates's 13F filing for Q2 2025, filed 7 Aug 2025.